眾生藥業(002317.SZ):擬贖回控股子公司眾生睿創部分股權
格隆匯3月26日丨眾生藥業(002317.SZ)公佈,公司收到公司控股子公司廣東眾生睿創生物科技有限公司(簡稱“眾生睿創”)其他股東江蘇紫金弘雲健康產業投資合夥企業(有限合夥)(簡稱“紫金弘雲”)、青島信鴻創業投資合夥企業(有限合夥)(簡稱“青島信鴻”)出具的《贖回通知》,要求公司按此前簽訂的《關於廣東眾生睿創生物科技有限公司之股東協議》的約定贖回其所持有眾生睿創的股權。根據《股東協議》約定,眾生睿創未能在2024年12月31日之前實現合格上市,已觸發贖回事件之一。公司擬使用自有資金人民幣11,257.4866萬元贖回紫金弘雲、青島信鴻合計所持有的眾生睿創2.63%股權。本次贖回完成後,公司對眾生睿創的持股比例由70.97%變為73.60%,眾生睿創仍為公司控股子公司。同意授權公司董事長根據具體情況實施相關事宜並簽署有關文件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.